Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KSP-0930
- Development stage
- Unknown
- Lead developer
- Kissei Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KSP-0930 is an orally active, small molecule orexin-2 receptor (OX2R) agonist being developed by Kissei Pharmaceutical for the treatment of narcolepsy type 1. Narcolepsy type 1 is a chronic neurological disorder characterized by excessive daytime sleepiness and cataplexy, primarily caused by the loss of orexin-producing neurons in the hypothalamus. By acting as a selective agonist for the OX2R, KSP-0930 aims to mimic the activity of endogenous orexin, thereby promoting wakefulness and stabilizing sleep-wake cycles. The drug is currently undergoing Phase 1 clinical evaluation in Japan to assess its safety, tolerability, and pharmacokinetics in both healthy volunteers and patients with narcolepsy.
02
Targets
HCRTR2 (Orexin/hypocretin receptor type 2)
Beyond the preview
Go deeper on KSP-0930.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KSP-0930.